Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.Interim CEO Jake Leach said the ...

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

DexCom was named a Barron’s stock pick in July. After DexCom shifted its focus to the Type 2 population last year, Type 1 ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst ...

Thinking about buying or holding DexCom stock? You’re not alone. Whether you’re a long-term investor or just looking for a timely healthcare pick, DexCom probably caught your attention for its role in ...